Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Migenix has initiated enrollment in a phase IIb combination therapy clinical trial of Celgosivir, the company's first-in-class alpha glucosidase 1 inhibitor, in development for the treatment of chronic hepatitis C virus infections. Results of the study are anticipated in mid-2006.
Subscribe to our email newsletter
In preclinical studies, Celgosivir has demonstrated strong synergy with interferon-alpha with and without ribavirin and has the potential to be included as part of a combination therapeutic approach to improve efficacy and/or tolerability.
A recently completed phase IIa monotherapy study demonstrated that the drug was well tolerated with some evidence of antiviral activity in treatment-naive chronic HCV patients.
“With the large market potential and unmet need in current hepatitis C treatment, Celgosivir is an important component of our value proposition in the short-term. Based on its strong demonstration of synergy in non-clinical studies to date, Celgosivir shows great promise as part of a combination therapy approach to improving the success of treatment for patients suffering from chronic hepatitis C infections,” said Dr Jim DeMesa, president and CEO of Migenix.